Novavax stock crumbled Monday after the Food and Drug Administration signed off on updated Covid boosters from rivals Pfizer and Moderna. Pfizer controls this market even though NVAX has an approval.

Covid is coming back this fall. No therapeutic for severe.

Covid with Pfizer paxlovid and vaccine will be a tough market to crack.